Leucine provides a digital twin of the pharma manufacturing shop floor, offering real-time performance monitoring, compliance management, and automated creation of electronic batch manufacturing records (eBMRs). Its platform uses proprietary LLM-based models to convert paper SOPs into digital workflows, enable root-cause analysis of deviations, and deliver actionable advice to improve efficiency. The company says it can onboard customers in about eight weeks and can reduce the digitization cycle of a batch from six-to-eight weeks to three-to-five days. Leucine monetizes via a tiered SaaS pricing model that scales with volume. The product is used by more than 30 companies across 300+ pharmaceutical manufacturing facilities in 10 countries, and Leucine reports 100% growth in facilities and a 300% increase in users over the last 12 months. Future plans include expanding the platform suite across the pharmaceutical manufacturing ecosystem and improving its AI co-pilot; the company also launched a beta of Leucine 10X, an AI framework that digitizes SOPs and creates dynamic production plans.

Total raised

$7M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2023